CSL (CSLLY) EBITDA per Share: $0.54 (TTM As of Dec. 2025)


CSLLY CSL Ltd CSLLY
73 GF Score
Price $19.98
GF Value $50.49
Valuation Significantly Undervalued
! 7 Warning Signs
View Full Analysis

What is CSL EBITDA per Share?

CSL CSLLY -2.30% 73 EBITDA per Share is $0.54 as of Dec. 2025. GuruFocus rates CSLLY with a GF Score™ of 73/100 and a GF Value™ of $50.49 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 1,144 Biotechnology companies, CSL ranks better than 50.87% on this metric.

CSL's EBITDA per Share for the six months ended in Dec. 2025 was $0.54. Its EBITDA per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.54.

During the past 12 months, the average EBITDA per Share Growth Rate of CSL was -77.70% per year. During the past 3 years, the average EBITDA per Share Growth Rate was 15.60% per year. During the past 5 years, the average EBITDA per Share Growth Rate was 10.80% per year. During the past 10 years, the average EBITDA per Share Growth Rate was 12.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per Share growth rate using EBITDA per Share data.

The historical rank and industry rank for CSL's EBITDA per Share or its related term are showing as below:

CSLLY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -1.3   Med: 14.8   Max: 64.6
Current: 15.6

During the past 13 years, the highest 3-Year average EBITDA per Share Growth Rate of CSL was 64.60% per year. The lowest was -1.30% per year. And the median was 14.80% per year.

CSLLY's 3-Year EBITDA Growth Rate is ranked better than
50.87% of 1144 companies
in the Biotechnology industry
Industry Median: 14.85 vs CSLLY: 15.60

CSL's EBITDA for the six months ended in Dec. 2025 was $1,062 Mil.

During the past 12 months, the average EBITDA Growth Rate of CSL was -77.50% per year. During the past 3 years, the average EBITDA Growth Rate was 16.90% per year. During the past 5 years, the average EBITDA Growth Rate was 12.50% per year. During the past 10 years, the average EBITDA Growth Rate was 12.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 13 years, the highest 3-Year average EBITDA Growth Rate of CSL was 69.60% per year. The lowest was -3.10% per year. And the median was 15.70% per year.


CSL  (OTCPK:CSLLY) EBITDA per Share Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals EBIT. EBIT is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost, it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies.


CSL EBITDA per Share Related Terms


CSL EBITDA per Share Historical Data

* Premium members only.

The historical data trend for CSL's EBITDA per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CSL EBITDA per Share Chart

CSL Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
EBITDA per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.99 1.84 2.01 2.44 2.64

CSL Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Jun25 Dec25
EBITDA per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.70 1.56 0.88 0.00 0.54
CSLLY
73GF Score
CSL Ltd CSLLY
EBITDA per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CSL EBITDA per Share Calculation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

CSL's EBITDA per Share for the fiscal year that ended in Jun. 2025 is calculated as

EBITDA per Share(A: Jun. 2025 )
=EBITDA/Shares Outstanding (Diluted Average)
=5134/1946.191
=2.64

CSL's EBITDA per Share for the quarter that ended in Dec. 2025 is calculated as

EBITDA per Share(Q: Dec. 2025 )
=EBITDA/Shares Outstanding (Diluted Average)
=1062/1956.098
=0.54

EBITDA per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.54

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA per Share →
What does a EBITDA per Share of $0.54 mean?
CSL (CSLLY) has a EBITDA per Share of $0.54 as of Dec. 2025. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on CSL and its competitors. According to the industry distribution chart, CSL ranks #562 out of 1144 companies in the Biotechnology industry, placing it in the top 49.1%.
Is CSL's EBITDA per Share too high?
CSL's current EBITDA per Share is $0.54. The Biotechnology industry median EBITDA per Share is 14.85. CSL's value of $0.54 is 96.4% below this industry median. Based on the distribution chart, CSL ranks #562 out of 1144 companies in the Biotechnology industry, which is above the industry midpoint. Overall, CSL has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CSL's EBITDA per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CSL ranks #562 out of 1144 companies for EBITDA per Share. This puts CSL in the upper half of its industry. The industry median EBITDA per Share is 14.85. CSL's value of $0.54 is 96.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA per Share for a Biotechnology company?
The median EBITDA per Share among Biotechnology companies is 14.85, based on 1,144 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA per Share significantly above this median, while those in the bottom quartile fall well below. However, EBITDA per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CSL's current EBITDA per Share of $0.54 is 96.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA per Share mean?
A high EBITDA per Share can signal that a stock is expensive relative to its fundamentals. EBITDA per share is the per-share amount of earnings before interest, taxes, depreciation and amortization. View historical data on CSL and its competitors. For the Biotechnology industry, the median EBITDA per Share is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CSL's current EBITDA per Share is $0.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
Based on GuruFocus' analysis, CSL (CSLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $50.49, compared to a current price of $19.98 — trading 60.4% below its estimated fair value. The current EBITDA per Share is $0.54 and 96.4% below the Biotechnology industry median of 14.85. CSL's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA per Share calculated?
EBITDA per Share is calculated from a company's financial statements. For CSL (CSLLY), the current EBITDA per Share is $0.54 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CSL (CSLLY) Overvalued in 2026?

Based on GuruFocus' analysis, CSL stock appears to be undervalued. The current stock price of $19.98 is trading 60.4% below its estimated GF Value™ of $50.49. GuruFocus considers CSL to be Significantly Undervalued.

Key valuation signals for CSLLY:

  • EBITDA per Share: $0.54
  • GF Value™: $50.49 vs. price of $19.98 (60.4% below fair value)
  • GF Score™: 73/100 with 7 warning signs
  • Industry Position: 96.4% below the Biotechnology median (#562 of 1144)

No single metric tells the full story. See the CSLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


CSL Business Description

Address 655 Elizabeth Street, Melbourne, VIC, AUS, 3000
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
73GF Score

Get the complete analysis for CSLLY

EBITDA per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.98
Price
$50.49
GF Value